Treatment of High-Risk NMIBC: What's New? w/ Dr. Ashish Kamat | Urology Podcast Ep. 177

In this episode of the BackTable Urology Podcast, Dr. Ashish Kamat discusses contemporary management of high-risk, non-muscle-invasive bladder cancer (NMIBC) and his thoughts into the future of this arena.
---
CHECK OUT OUR SPONSOR
Siemens Healthineers Theranostics
www.siemens-healthineers.com/...
---
SYNPOSIS
Dr. Kamat explores the evolving role of BCG and potential alternative therapies such as gemcitabine and docetaxel. He also covers effective clinical management, emerging clinical trials, and nuanced decision-making principles for radical cystectomy. Finally, the conversation touches on Dr. Kamat’s expert insights regarding the future of NMIBC management, including predictive biomarkers and personalized medicine.
---
TIMESTAMPS
00:00 - Introduction
03:56 - Initial Diagnosis and Workup
12:22 - High-Grade Bladder Cancer
22:37 - BCG and Alternative Treatments
31:30 - BCG Unresponsive Disease
36:56 - Novel Intravesical and Systemic Therapies
46:45 - Future Directions
---
RESOURCES
Related BackTable episodes:
www.backtable.com/shows/urolo...
www.backtable.com/shows/urolo...
www.backtable.com/shows/urolo...
---
The BackTable Urology Podcast is a resource for practicing urologists to learn tips, techniques, and practical advice from their peers in the field. Listen on BackTable.com/Urology or on the streaming platform of your choice.
Get notified when new episodes drop! Subscribe to the BackTable Urology Podcast on your go-to podcast platform, and follow us on your social media platform of choice for regular updates.
► www.backtable.com/shows/urolo...
#nmibc #bladdercancer #urologiconcology #URO177

[@Happy36]

When was this actually recorded? It’s showing today, July 9, 2024, but the information appears to be older than this date. Thanks